Clinical trial Recruiting at 1 site Observational Ages 45 to 70 Women only

Bone marrow fat changes after gastric bypass versus sleeve in postmenopausal women

Official title: Bone Marrow Fat and Bariatric Surgery-Mediated Bone Loss

Run by University Hospital, Lille · NCT05005039 · Data updated 2026-11-12

This study will test whether bone marrow fat changes differently after gastric bypass (RYGB) versus sleeve gastrectomy (SG) in postmenopausal women with obesity and whether those changes relate to diabetes status and metabolic or hormonal markers.

Quick facts

Study typeObservational
Ages45 Years to 70 Years
SexWomen only
Enrollment40 (estimated)
SponsorUniversity Hospital, Lille
Academic / other
Drugs / interventionsdenosumab, radiation
Locations1 site (Lille)
StatusRecruiting
StartedApril 20, 2022
Main results expectedJune 2027
Study endsJune 2027
Registry record updatedApril 20, 2026
Trial IDNCT05005039 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are postmenopausal women (last menses >12 months) with BMI ≥35 kg/m² who are scheduled for their first RYGB or SG and who do not have major conditions or treatments affecting bone metabolism.

Probably not a fit

Patients already on anti-osteoporotic therapy, recent corticosteroid treatment, or with conditions that affect bone metabolism (for example uncontrolled hyperthyroidism, primary hyperparathyroidism, or recent spine/hip radiation) are unlikely to benefit and may be excluded.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational study enrolling postmenopausal women with obesity who are scheduled for first-time RYGB or SG to measure bone marrow fat fraction (BMFF) before and after surgery. Participants will undergo imaging to quantify BMFF and blood tests to profile glycemic control, lipids, adipokines (leptin, adiponectin), calciotropic hormones, and other candidate mediators such as G-CSF. The primary analytic approach compares BMFF changes between surgical types and by diabetic status, and explores correlations between BMFF change and metabolic/hormonal factors. The goal is to identify patterns and potential biological mediators that might explain bariatric surgery–associated bone loss.

Why it matters

Potential benefit: If successful, the findings could help identify mechanisms of bone loss after bariatric surgery and inform strategies to protect bone health in this population.

How similar studies have gone: Prior studies have reported inconsistent results and no single molecular mechanism has been confirmed, so this observational approach is exploratory rather than building on a clearly established success.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Postmenopausal women (defined as last menses \>12 months)

* Obesity with a BMI ≥ 35 kg/m²,
* Patients with an indication for bariatric surgery with two surgical techniques, RYGB and SG, but who have never had a bariatric surgery procedure previously,
* Patients who have signed the informed consent.

Exclusion Criteria:

* History of an osteoporotic fracture 2- Current corticosteroid therapy or corticosteroid therapy within the past 3 months, C-onditions or treatments affecting bone metabolism (breast cancer treated with aromatase inhibitors, malabsorption, stomach cancer, primary hyperparathyroidism, uncontrolled hyperthyroidism…),
* History of radiation therapy to the lumbar spine or the hip being studied,
* Patients on hormone replacement therapy (HRT) or patients already on anti-osteoporotic treatment (bisphosphonates, strontium ranelate, teriparatide, or denosumab) other than calcium and/or vitamin D supplementation,
* Chronic kidney disease with a creatinine clearance (CKD-EPI formula) ≤ 30 mL/min,
* Weight \> 160 kg, as the bone densitometer table is limited to this weight for the examination,
* Patients who have previously undergone bariatric surgery,
* Patients with orthopedic implants in both hips or the lumbar spine,
* Individuals unable to give personal consent,
* Individuals under legal guardianship or conservatorship,
* Patients not enrolled in a social security program.
* Any contraindication to MRI: (claustrophobia, patients with a pacemaker/defibrillator, cochlear implant, neurostimulator, or orthopedic implants in the hip, pelvis, or lumbar spine, etc.).

Where it's running

  • Hopital Roger Salengro, CHU Lille
    Lille, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.